Abstract
SummaryThis publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
Funder
Medical University of Vienna
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Consensus Statement 2011 Österreichische Ärztezeitung. https://infektiologie.co.at/wp-content/uploads/2017/08/cs-tbc_u_biologika.pdf. Accessed 15 Aug 2022.
2. WHO-Global Tuberculosis Report. 2020. https://www.who.int/publications/i/item/9789240013131. Accessed 15 Aug 2022.
3. https://www.ages.at/themen/krankheitserreger/tuberkulose-tbc/. Accessed 15 Aug 2022.
4. WHO, editor. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
5. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–6. https://doi.org/10.3899/jrheum.150051.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献